Glaukos

Laguna Hills, United States Founded: 2001 • Age: 25 yrs
Developer of implants to treat glaucoma
Request Access

About Glaukos

Glaukos is a company based in Laguna Hills (United States) founded in 2001.. Glaukos has raised $117.57 million across 10 funding rounds from investors including Orbimed, Frazier Healthcare Partners and Meritech Capital. The company has 995 employees as of December 31, 2024. Glaukos has completed 1 acquisition, including Avedro. Glaukos operates in a competitive market with competitors including Ivantis, Myra Vision, Transcend Medical, InnFocus and AqueSys, among others.

  • Headquarter Laguna Hills, United States
  • Employees 995 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Glaukos Corporation
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
    $383.48 M
    21.85
    as on Dec 31, 2024
  • Net Profit
    $-146.37 M
    -8.7
    as on Dec 31, 2024
  • EBITDA
    $-68.22 M
    20.42
    as on Dec 31, 2024
  • Total Equity Funding
    $117.57 M (USD)

    in 10 rounds

  • Latest Funding Round
    $250 M (USD), Post-IPO

    Jun 08, 2020

  • Investors
    Orbimed

    & 7 more

  • Employee Count
    995

    as on Dec 31, 2024

  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Glaukos

Glaukos is a publicly listed company on the NYSE with ticker symbol GKOS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NYSE · Ticker: GKOS . Sector: Health technology · USA
People of Glaukos
Headcount 500-1000
Employee Profiles 241
Board Members and Advisors 6
Employee Profiles
People
Valerie C.
Manager, Clinical Operations
People
Thomas W. Burns
President & CEO
People
Wilfredo Perez
Senior Quality Assurance Engineer Ll ( Medical Device)
People
Jay L. Katz
Chief Medical Officer

Unlock access to complete

Board Members and Advisors
people
Mark J. Foley
Director
people
Aimee S. Weisner
Director
people
Gilbert H. Kliman
Director
people
Marc A. Stapley
Director

Unlock access to complete

Funding Insights of Glaukos

Glaukos has successfully raised a total of $117.57M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $250 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 10
  • Last Round Post-IPO — $250.0M
  • First Round

    (01 Sep 2002)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2020 Amount Post-IPO - Glaukos Valuation

investors

Jan, 2013 Amount Series E - Glaukos Valuation Meritech
Oct, 2012 Amount Series E - Glaukos Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Glaukos

Glaukos has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Frazier Healthcare Partners and Meritech Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Private equity investments are directed toward US-based companies.
Founded Year Domain Location
Life science & tech focused VC firm investing in the US
Founded Year Domain Location
Healthcare sector private equity investments are managed by the firm.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Glaukos

Glaukos has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Avedro. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Corneal collagen cross-linking technology is developed for ophthalmic applications.
2007
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Glaukos

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Glaukos Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Glaukos

Glaukos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ivantis, Myra Vision, Transcend Medical, InnFocus and AqueSys, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Implantable device to relieve intraocular pressure in open angle glaucoma
domain founded_year HQ Location
Nanotechnology-based devices for glaucoma treatment are developed.
domain founded_year HQ Location
Minimally invasive glaucoma stents are developed to enhance aqueous outflow.
domain founded_year HQ Location
Glaucoma is treated via the implantable MicroShunt device in ophthalmology.
domain founded_year HQ Location
Implantable devices for glaucoma treatment are developed by AqueSys.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Glaukos

Frequently Asked Questions about Glaukos

When was Glaukos founded?

Glaukos was founded in 2001 and raised its 1st funding round 1 year after it was founded.

Where is Glaukos located?

Glaukos is headquartered in Laguna Hills, United States. It is registered at Laguna Hills, California, United States.

Is Glaukos a funded company?

Glaukos is a funded company, having raised a total of $117.57M across 10 funding rounds to date. The company's 1st funding round was a Series E of $6M, raised on Sep 01, 2002.

How many employees does Glaukos have?

As of Dec 31, 2024, the latest employee count at Glaukos is 995.

What is the annual revenue of Glaukos?

Annual revenue of Glaukos is $383.48M as on Dec 31, 2024.

What does Glaukos do?

The company was founded in 2001 and is headquartered in Laguna Hills, United States, within the medical devices sector focused on ophthalmology. Operations center on the development of the Micro-Invasive Glaucoma Surgery (MIGS) method, including the iStent device, which is implanted during cataract surgery to reduce intraocular pressure. Additional platforms for bioerodible drug delivery targeting retinal disorders are also being advanced.

Who are the top competitors of Glaukos?

Glaukos's top competitors include Myra Vision, Avisi Technologies and Sanoculis.

Is Glaukos publicly traded?

Yes, Glaukos is publicly traded on NYSE under the ticker symbol GKOS.

How many acquisitions has Glaukos made?

Glaukos has made 1 acquisition, including Avedro.

Who are Glaukos's investors?

Glaukos has 8 investors. Key investors include Orbimed, Frazier Healthcare Partners, Meritech Capital, Domain Associates, and InterWest.

What is Glaukos's ticker symbol?

The ticker symbol of Glaukos is GKOS on NYSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available